This is a working overview of freeze-thaw, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-03. Anything still debated is marked as such rather than presented as settled.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Verification of research-grade material depends on documentation supplied with a sample. A certificate of analysis lists purity, identity, and the methods used to establish each value. Buyers comparing suppliers look at chromatographic purity figures, mass confirmation data, and whether methods are described in enough detail to be reproduced. Independent testing can confirm reported values but adds cost and time. Because the research chemical market is not uniformly regulated, provenance and documentation quality vary widely, and claims should be evaluated against raw data rather than summary labels.
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
Material handling focuses on limiting degradation. Lyophilized powder is generally stored at reduced temperature, often around minus twenty degrees Celsius, protected from light and moisture. Once dissolved, the peptide is less stable and is commonly kept cold and used within a short window. Repeated freeze-thaw cycles promote aggregation and should be avoided. Buffers and pH influence stability, and solution conditions are usually selected to keep the peptide near neutral pH where degradation proceeds more slowly. These practices apply to laboratory reference material, not to clinical preparations.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
== History == Thiobuscaline was first described in the scientific literature by Alexander Shulgin and Peyton Jacob III in 1984. Subsequently, it was described in greater detail by Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991.
On average, groups of people with "obese" BMIs may have a higher risk of developing illnesses like diabetes, hypertension, dyslipidemia (high cholesterol), liver disease, and some cancers. "Underweight" BMIs may indicate malnutrition or other health problems. However, BMI has limitations when used to describe individual health rather than describing populations of people.
In March 1916 (BR.23–BR.26), Robertson announced the results of a series of experiments that he and his assistant, Louis Adolph Ray, had conducted with the white mice — chosen as his "experimental animal" because of their "hardiness, rapid growth, smallness, and fecundity" (BR.23, p.366) — wherein the oral administration of tethelin, a "growth-controlling principle" (which they later described as "the ether-precipitable fraction of an alcoholic extract of the anterior lobe of the pituitary body"), produced precisely "the same effects on their growth" as those "which [had] accompan[ied] the [oral] administration of the whole tissue of the anterior lobe of the pituitary body" to his control group (BR.25, p.397). As Everitt (AE.2, p.63) notes — having distinguished (p.66) Robertson and Ray's "growth controlling principle" of the pituitary (BR.35) from Moon, et al.'s "growth stimulating principle" (HM.2) — it was not until the (1921) work of Herbert Evans and Joseph Long (HE.1; HE.2) that "[it was] conclusively proved that the pituitary contained a growth-stimulating hormone". Evans and Long also discovered that, whilst the oral administration of their "pituitary principle" had no effect, administration per medium of an intraperitoneal injection was effective: which led them to the conclusion that whatever the pituitary's 'active principle' might be, it was "digested in the alimentary canal".
A study treated non-diabetic, healthy men with the GLP-1 receptor antagonist (i.e., blocker of receptor activation) exendin(9-39)NH2a (also termed avexitide), the GIP receptor antagonist GIP(3-30)NH2, or both antagonists and challenged them with an oral glucose tolerance test. Men treated with either agent responded to the tolerance test with modest decreases in blood insulin levels and modest increases in blood glucose levels. However, men treated with both antagonists responded with very low insulin and very high glucose blood levels: their responses were similar to those in individuals with type 2 diabetes. This study shows that 1) the stimulation of the FFAR2 on K and L cells by SCFAs underlies the differences between oral and intravenous glucose challenges defined by the incretin effect and 2) FFAR2 functions to regulate blood insulin and glucose levels. This does not prove that type 2 diabetes is a FFAR2-incretin disease: post-feeding secretion of the incretins (i.e., GLP-1 and GIP) is impaired in type 2 diabetes, but the impairment appears to result primarily from decreases in the responsiveness of pancreas alpha cells to GLP-1. This conclusion is supported by studies showing that type 2 diabetic individuals who are treated with large amounts of GLP-1 and challenged with intravenous glucose show changes in blood insulin and glucose levels that are similar to those in non-diabetic individuals. Indeed, GLP-1 agonists, e.g., Dulaglutide, and a first-in-kind GLP-1 and GIP agonist, Tirzepatide, are used to treat type 2 diabetes.
A fascia (; pl.: fasciae or fascias; adjective fascial; from Latin fascia 'band') is a generic term for macroscopic membranous bodily structures. Fasciae are classified as superficial, visceral or deep, and further designated according to their anatomical location. The knowledge of fascial structures is essential in surgery, as they create borders for infectious processes (for example Psoas abscess) and haematoma. An increase in pressure may result in a compartment syndrome, where a prompt fasciotomy may be necessary. For this reason, profound descriptions of fascial structures are available in anatomical literature from the 19th century.
Sources: en.wikipedia.org
=== Sports injuries === According to several studies, creatine supplements decrease or at least do not increase the incidence of musculoskeletal injury, muscle cramping, and dehydration. In a study, creatine users had fewer incidences than non-users of muscle pulls/strains, muscle tightness, cramping, heat illness/dehydration, non-contact injuries, and total injuries/missed practices.
=== Winning streak === Next, Pudzian faced former bodybuilder Erko Jun on 9 November 2019 at KSW 51: Croatia. He won the bout via second round TKO. Pudzianowski was then scheduled to headline KSW 53 against Quentin Domingos on 21 March 2020 before the bout was scrapped due to Pudzianowski's injury. Pudzianowski was set to return after a fifteen month layoff against the undefeated Senegalese heavyweight Serigne Ousmane at KSW 59: Fight Code on 20 March 2021. However, on the day of the fight, Ousmane Dia suffered an acute appendicitis attack and had to be hospitalized. Stepping in on just a few hours notice was Serbia's Nikola Milanovic. Pudzianowski won the bout via TKO in the first round. Pudzianowski faced KSW 1 tournament winner Łukasz Jurkowski on 5 June 2021 at KSW 63: Crime of The Century. Pudzianowski won the fight via TKO in the 3rd round. The fight with Serigne Ousmane Dia was then rebooked and took place at KSW 64: Przybysz vs. Santos on 23 October 2021. Pudzianowski won the fight via knockout 18 seconds into round one. Pudzianowski faced former KSW Middleweight champion Michał Materla at KSW 70: Pudzianowski vs. Materla on 28 May 2022. He won the bout in the first round, knocking out Materla with an uppercut. He was awarded the Knockout of the Night bonus with the win. Pudzianowski faced former two-division champion Mamed Khalidov at KSW 77: Khalidov vs. Pudzianowski on 17 December 2022. Pudzian's 6-win streak was ended after he tapped to ground and pound in the first round.
== Management == Primary treatment is prompted by the administration of adequate doses of either the thyroid hormone L-thyroxine given intravenously or by giving liothyronine via a nasogastric tube. It is essential to identify and treat the condition precipitating the coma. Myxedema coma is rare but often fatal. It occurs most often in elderly women and may be mistaken for one of the chronic debilitating diseases common to this age group. Gabrilove et al demonstrated that histological skin changes can be observed within 3-4 weeks after initiating thyroid hormone replacement therapy with desiccated thyroid extract. This was documented through skin biopsies performed on individuals with hypothyroidism both before and after treatment. The magnitude of these effects was related to the dose of thyroid hormone administered, and the rate at which this occurred depended on the amounts of material present at the outset. Though the exact cause of myxedema is still unclear, a wealth of research has demonstrated the importance of iodine. In an important study the researchers showed that in the myxedematous type of cretinism treatment with iodine normalizes thyroid function provided that the treatment is begun early in the postnatal period. If not, the prognosis remains dismal.
At first sight this appears to offer a means of obtaining the standard molar enthalpy of the reaction by studying the variation of K with temperature. In practice, however, the method is unreliable because error propagation almost always gives very large errors on the values calculated in this way.
Sources: en.wikipedia.org
RBR and HBR were defined in the initial release of the DisplayPort standard, version 1.0 HBR2 was introduced in version 1.2 HBR3 was introduced in version 1.3 UHBR10, UHBR13.5, and UHBR20 were introduced in version 2.0 However, transmission mode support is not necessarily dictated by a device's claimed "DisplayPort version number". For example, older versions of the DisplayPort Marketing Guidelines allowed a device to be labeled as "DisplayPort 1.2" if it supported the MST feature, even if it didn't support the HBR2 transmission mode. Newer versions of the guidelines have removed this clause, and currently (as of the June 2018 revision) there are no guidelines on the usage of DisplayPort version numbers in products. DisplayPort "version numbers" are therefore not a reliable indication of what transmission speeds a device can support. In addition, individual devices may have their own arbitrary limitations beyond transmission speed. For example, NVIDIA Kepler GK104 GPUs (such as the GeForce GTX 680 and 770) support "DisplayPort 1.2" with the HBR2 transmission mode, but are limited to 540 Mpx/s, only 3⁄4 of the maximum possible with HBR2. Consequently, certain devices may have limitations that differ from those listed in the following tables. To support a particular format, the source and display devices must both support the required transmission mode, and the DisplayPort cable must also be capable of handling the required bandwidth of that transmission mode. (See: Cables and connectors)
== Side effects == Miconazole is generally well tolerated. The oral gel can cause dry mouth, nausea and an unpleasant taste in about 1–10% of people. Anaphylactic reactions are rare. The drug prolongs the QT interval.
Milk production can be induced in transgender women by the use of hormone medication, usually a galactagogue similarly to induced lactation in cisgender women, with domperidone being a common choice. Induced lactation without the use of galactagogues has also been demonstrated in at least two cases using a modified feminizing hormone therapy featuring progesterone and nipple stimulation, with eventual successful production of breast milk. In one case report, a transgender woman was able to produce 7 mL of milk per day with hormone treatment. A different transgender woman was able to produce 8 oz of milk per day achieving "sufficient breast milk volume to be the sole source of nourishment for her child for six weeks." Several studies analyzing milk samples from trans women have found them to contain nutrients within parameters suitable for nursing. A 2018 survey of medical professionals with attending a WPATH event where 34% of the surveyed professionals had met a transgender patient expressing interest in induced lactation, 21% of them knew of providers who facilitated lactation for transgender patients, and 9% had themselves helped trans women induce lactation.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
Purity is usually reported from reversed-phase high-performance liquid chromatography with ultraviolet detection. Peak area percentage gives a purity figure, though it does not prove identity. Mass spectrometry is used alongside chromatography to confirm the expected molecular mass.